Drug Trial Radar · NCT00709852
Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging
Last checked: Nov 19, 2026Latest source record: Dec 30, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
402
Actual
Start
Jun 2008
Primary completion
Apr 2009
Study completion Apr 2009
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Jul 3, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study involves the use of Magnetic Resonance Imaging (MRI) contrast agents called gadobutrol (Gadavist) Injection and ProHance Injection. The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of gadobutrol when used for taking MR images of the brain and spine. The results of the MRI with gadobutrol Injection will be compared to the results of MR images taken without contrast and with the results of the MR images taken with ProHance.
Conditions
- Diagnostic Imaging
- Central Nervous System Diseases
Interventions
Gadobutrol (Gadavist, Gadovist, BAY86-4875)Drug
Participants received a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous)
Gadoteridol (ProHance)Drug
Participants received a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic Resonance Imaging (MRI) Compared to Unenhanced MRI by Blinded Reader 1 (BR1)Time frame: Up to 2 hours after injection of gadobutrol
- Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic Resonance Imaging (MRI) Compared to Unenhanced MRI by Blinded Reader 2 (BR2)Time frame: Up to 2 hours after injection of gadobutrol
- Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic Resonance Imaging (MRI) Compared to Unenhanced MRI by Blinded Reader 3 (BR3)Time frame: Up to 2 hours after injection of gadobutrol
- Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic Resonance Imaging (MRI) Compared to Unenhanced MRI by Average Reader (AR)Time frame: Up to 2 hours after injection of gadobutrol
- Number of Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded ReadersTime frame: Up to 2 hours after injection of gadobutrol
- Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Normal Structures for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 1 (BR1)Time frame: Up to 2 hours after injection of gadobutrol
- Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Normal Structures for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 2 (BR2)Time frame: Up to 2 hours after injection of gadobutrol
- Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Normal Structures for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 3 (BR3)Time frame: Up to 2 hours after injection of gadobutrol
- Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Normal Structures for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Average Reader (AR)Time frame: Up to 2 hours after injection of gadobutrol
- Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 1 (BR1)Time frame: Up to 2 hours after injection of gadobutrol
- Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 2 (BR2)Time frame: Up to 2 hours after injection of gadobutrol
- Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 3 (BR3)Time frame: Up to 2 hours after injection of gadobutrol
- Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Average Reader (AR)Time frame: Up to 2 hours after injection of gadobutrol
Locations
79 sites in 8 countries. Site status is shown where the registry gives one.
West Alabama Research, Inc.
Birmingham, Alabama
Achieve Clinical Research, LLC
Tuscaloosa, Alabama
Los Gatos MRI
Los Gatos, California
Hoag Memorial Hospital Presbyterian
Newport Beach, California
Redwood Regional Medical Group, Inc.
Santa Rosa, California
University of Florida - Jacksonville
Jacksonville, Florida
NorthShore University HealthSystem-Evanston Hospital
Evanston, Illinois
Atchison Hospital
Atchison, Kansas
University of Maryland Hospital System
Baltimore, Maryland
Johns Hopkins Hospital/Health System
Baltimore, Maryland
Shields MRI - Brockton
Brockton, Massachusetts
VA Boston Healthcare System-West Roxbury Division
West Roxbury, Massachusetts
Washington University School of Medicine
St Louis, Missouri
University of New Mexico School of Medicine
Albuquerque, New Mexico
Kingston Neurological Associates, PC
Kingston, New York
NYU Hospital for Joint Diseases
New York, New York
Duke University Medical Center
Durham, North Carolina
The Cleveland Clinic
Cleveland, Ohio
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Allegheny General Hospital
Pittsburgh, Pennsylvania
Rhode Island Hospital
Providence, Rhode Island
Medical University of South Carolina
Charleston, South Carolina
University of Washington Medical Center
Seattle, Washington
Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
St George Hospital
Kogarah, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Monash Medical Centre
Clayton, Victoria, Australia
Landeskrankenhaus Donauregion Tulln
Tulln, Lower Austria, Austria
Allgemeines Krankenhaus der Stadt Wien Universitätskliniken
Vienna, State of Vienna, Austria
Medizinische Universität Graz
Graz, Styria, Austria
LNK Wagner Jauregg
Linz, Upper Austria, Austria
Centro de Diagnostico Medico
Medellín, Colombia
Fundación Instituto de Alta tecnología médica de Antioquia
Medellín, Antioquia, Colombia
Fundación Santa Fe de Bogotá - Hospital Universitario
Bogotá, Cundinamarca, Colombia
DIME Clinica Neurocardiovascular S.A.
Cali, Valle del Cauca Department, Colombia
Deutsches Krebsforschungszentrum
Heidelberg, Baden-Wurttemberg, Germany
Städtisches Klinikum Karlsruhe gGmbH
Karlsruhe, Baden-Wurttemberg, Germany
Klinikum Mannheim gGmbH
Mannheim, Baden-Wurttemberg, Germany
Zentralklinikum Augsburg
Augsburg, Bavaria, Germany
Showing 40 of 79 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.